105 related articles for article (PubMed ID: 21566651)
1. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies.
Wickremasinghe RG; Prentice AG; Steele AJ
Leukemia; 2011 Sep; 25(9):1400-7. PubMed ID: 21566651
[TBL] [Abstract][Full Text] [Related]
2. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network.
Audrito V; Vaisitti T; Rossi D; Gottardi D; D'Arena G; Laurenti L; Gaidano G; Malavasi F; Deaglio S
Cancer Res; 2011 Jul; 71(13):4473-83. PubMed ID: 21565980
[TBL] [Abstract][Full Text] [Related]
3. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel O; Wacht N; Sifft E; Melchardt T; Hamacher F; Kocher T; Denk U; Hofbauer JP; Egle A; Scheideler M; Schlederer M; Steurer M; Kenner L; Greil R
Leukemia; 2012 Dec; 26(12):2508-16. PubMed ID: 22743622
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
5. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
6. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Nacheva EP; Howard-Reeves JD; Duke VM; Kottaridis PD; Cwynarski K; Vassilev LT; Wickremasinghe RG
Blood; 2008 Nov; 112(9):3827-34. PubMed ID: 18682598
[TBL] [Abstract][Full Text] [Related]
7. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
8. [Notch signal pathway and chronic lymphocytic leukemia].
Zhang JY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1472-5. PubMed ID: 25338610
[TBL] [Abstract][Full Text] [Related]
9. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
10. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells.
Moon EY; Lerner A
Cancer Res; 2002 Oct; 62(20):5711-9. PubMed ID: 12384529
[TBL] [Abstract][Full Text] [Related]
11. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt AR; Sherrington PD; Cawley JC
Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
[TBL] [Abstract][Full Text] [Related]
12. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro.
Steele AJ; Jones DT; Ganeshaguru K; Duke VM; Yogashangary BC; North JM; Lowdell MW; Kottaridis PD; Mehta AB; Prentice AG; Hoffbrand AV; Wickremasinghe RG
Leukemia; 2006 Jun; 20(6):1073-9. PubMed ID: 16628188
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
14. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
[TBL] [Abstract][Full Text] [Related]
16. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
Jones GG; Reaper PM; Pettitt AR; Sherrington PD
Oncogene; 2004 Mar; 23(10):1911-21. PubMed ID: 14755251
[TBL] [Abstract][Full Text] [Related]
17. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.
Amrein L; Soulières D; Johnston JB; Aloyz R
Leuk Res; 2011 Jan; 35(1):99-102. PubMed ID: 20573397
[TBL] [Abstract][Full Text] [Related]
18. Activity of the notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells.
Hajdu M; Sebestyén A; Barna G; Reiniger L; Jánosi J; Sréter L; Várkonyi J; Demeter J; Kopper L
Scand J Immunol; 2007 Mar; 65(3):271-5. PubMed ID: 17309782
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Christian BA; Grever MR; Byrd JC; Lin TS
Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
[TBL] [Abstract][Full Text] [Related]
20. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
